Oncolytic Virus Therapy - Foreword
H. Kasuya, S. Takeda, S. Shimoyama, T. Shikano, N. Nomura, N. Kanazumi, S. Nomoto, H. Sugimoto and A. Nakao
Pages 123-125 (3)
We are very pleased and proud to be able to publish this special issue of Current Cancer Drug Targets devoted to oncolytic virus therapy covering basic and clinical research on adenovirus, vaccinia virus, herpes virus, and Newcastle disease virus. In these papers, we welcome the worlds top authorities in the field who have generously contributed their latest review articles for exclusive publication in this special issue. Moreover, this issue also includes a range of opinion from government drug organizations. Here we simply wish to bring together the newest knowledge and experience in the field of cutting-edge oncolytic virus therapy for researchers and every kind of cancer therapist. The Foreword presents a historical perspective on the development of oncolytic virus together with the encouraging results of recent clinical trials (e.g., H101 has been tested in clinical trial of nearly 250 patients and approved for human use by the Chinese FDA, while PV701 has been tried in over 110 patients, as described in our special issue).
Oncolytic virus, gene therapy, adenovirus, vaccinia virus, herpes virus, Newcastle disease virus, HF10
Department of Surgery II, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550,Japan.